HanAll BioPharma Co., Ltd.

Quick facts

Phase 3 pipeline

• HL-040XC · Oncology
  HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
• HL036 Ophthalmic Solution · Ophthalmology
  HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.

Phase 2 pipeline

• HL-009 Liposomal Gel

Phase 1 pipeline

• ATH-399A
• ATH-399A 10 mg
• HL036
• HL040XC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• HanAll BioPharma Co., Ltd. portfolio CI brief
• HanAll BioPharma Co., Ltd. pipeline updates RSS